Details of the Drug

General Information of Drug (ID: DM3GYAL)

• Drug Name: Deoxycholic acid
• Synonyms: (3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate

Indication

Disease Entry	ICD 11	Status	REF
Subcutaneous fat disorder	EF02	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  D11AX24: Deoxycholic acid
  D11AX: Other dermatologicals
  D11A: OTHER DERMATOLOGICAL PREPARATIONS
  D11: OTHER DERMATOLOGICAL PREPARATIONS
  D: DERMATOLOGICALS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 392.58
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 4
  Hydrogen Bond Donor Count; 3
  Hydrogen Bond Acceptor Count; 4
• ADMET Property: Metabolism: The drug is not metabolised []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cell death	Not Available	DDT	OTF5HTYL	[2]
Cell death	Not Available	DCT	OTYVNTBG	[2]

• Chemical Identifiers:
  Formula: C24H40O4
  IUPAC Name: (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
  Canonical SMILES: CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
  InChI: InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
  InChIKey: KXGVEGMKQFWNSR-LLQZFEROSA-N
• Cross-matching ID:
  PubChem CID: 222528
  ChEBI ID: CHEMBL406393
  CAS Number: 83-44-3
  UNII: 005990WHZZ
  DrugBank ID: DB03619
  VARIDT ID: DR01301
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Drug Pharmacogenomic Perturbation (DPP)NEW: Click to Jump to the Detailed DPP Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Apical sodium-dependent bile acid transporter (SLC10A2)	DT7JELC	NTCP2_HUMAN	Substrate	[3]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Drug Response	[5]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)	OTRI4UR1	CP8B1_HUMAN	Gene/Protein Processing	[6]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Gene/Protein Processing	[6]
ATP-binding cassette sub-family G member 5 (ABCG5)	OT1OMY93	ABCG5_HUMAN	Gene/Protein Processing	[6]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[7]
Baculoviral IAP repeat-containing protein 1 (NAIP)	OTLA925F	BIRC1_HUMAN	Drug Response	[5]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Drug Response	[5]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Gene/Protein Processing	[6]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[8]
D-dopachrome decarboxylase (DDT)	OTF5HTYL	DOPD_HUMAN	Drug Response	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [3] Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
• [4] Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
• [5] Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis. 2002 Dec;23(12):2063-80. doi: 10.1093/carcin/23.12.2063.
• [6] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [7] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [8] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.